Niagen Bioscience Surges with New Analyst Buy Rating & Rising Volatility
Niagen Bioscience’s new “Buy” rating and rising option volatility point to fresh upside potential for the NAD⁺ biotech stock—watch its next move.
3 minutes to read
NIAGEN BIOSCIENCE INC
Niagen Bioscience Inc. Reports Strong Q2 2025 Performance with Significant Revenue Growth and Strategic Expansion
Niagen Bioscience Inc. reports strong Q2 2025 performance with 37% revenue growth and increased full-year financial outlook, positioning the company for sustained growth in the life sciences sector.
2 minutes to read
Niagen Bioscience Expands Niagen IV Reach to 600 Clinics, Eyes Earnings Growth
Niagen Bioscience Inc has expanded its flagship product, Niagen IV, to nearly 600 clinics nationwide, positioning the company for growth and increased market share in the healthy aging solutions sector.
2 minutes to read
Niagen Bioscience Expands Niagen IV Therapy to 600 U.S. Clinics, Boosting NAD+ Access for Healthy Aging
Niagen Bioscience Inc. has expanded the availability of its Niagen IV therapy, a pharmaceutical-grade NAD+ treatment, to nearly 600 clinics across the US, marking a significant increase in its clinical footprint.
2 minutes to read
Niagen Bioscience Appoints Dr. Pinchas Cohen, Sparking Hope for Scientific and Market Revival
Niagen Bioscience Inc has appointed Dr. Pinchas Cohen to its Scientific Advisory Board, a move that could redefine the company’s trajectory and drive innovation in the life sciences tools and services industry.
3 minutes to read